Salesforce’s new AI tools will help doctors manage patient care: The offerings stack Salesforce against other Big Tech players with AI solutions for the healthcare industry.
Biden takes aim at the healthcare industry: We unpack his ambitious agenda and lay out what to look out for, and what’s motivating the proposals.
FDA clears the first OTC continuous glucose monitor: Dexcom wants to sell CGMs to diabetics—and maybe to non-diabetics, too. We explore the pros and cons of this latest direct-to-consumer healthcare trend.
How physicians are using social media: We unpack what pharma brands need to know about docs’ social usage—and how marketers can connect with them on various platforms.
Mark Cuban’s next pharma foray: The billionaire’s drug company is getting more creative in how it’s tackling medication shortages and high Rx prices.
Cigna unveils healthcare solutions at investor day: The programs address hot-button healthcare issues and highlight its Evernorth business, as the industry fends off DC scrutiny
On today's podcast episode, we discuss what happened when the first human ever received a brain implant from Neuralink, the other potential benefits of this technology outside of helping people with paralysis, and what the ultimate goal of Neuralink actually is. "In Other News," we talk about what happens now that ChatGPT has a memory and what to make of Gemini's rough start. Tune in to the discussion with our analysts Jacob Bourne and Gadjo Sevilla.
Patients saddled with large amounts of medical debt often don’t pay up: Healthcare providers’ collection rates could continue to worsen. We detail the reasons why—and explore how they can improve.
Virta Health’s approach to lower-cost weight loss should please employers, health plans: People who stopped taking expensive weight-loss drugs but stuck with a low-carb diet kept the weight off, a new study shows.
D2C pharmacies face challenges stocking costly drugs: But a new study suggests Amazon Pharmacy has an advantage over rivals.
Lots of consumers are self-medicating: A new survey discloses the many reasons patients give for taking meds without a doc’s supervision. Marketers must pay closer attention to the worrisome trends of self-medication and self-diagnosis.
Independent pharmacies are getting squeezed: Facing financial pressure, a third of community pharmacies say they’re considering closing down. We look at what this means for patients and the industry.
UnitedHealth Group is facing an antitrust investigation: The probe could rein in the most dominant US healthcare company.
Vale Health’s new online marketplace vets health and wellness solutions for patients: Healthcare brands with products on the platform could see increased sales—here’s why.
Pharma is moving slowly on AI adoption: A new survey shows the drug industry’s tentative approach to AI tech. We unpack the reasons for this lag and show where AI will be put to work—from marketing to clinical trials.
Health system CEOs tackle gun violence: We explore how healthcare marketers and providers can work together on educating patients about gun violence prevention and safety.
Americans are coming around to weight loss drugs: Pharma has done a good job abating stigmas around the drugs with ads. Now, more companies want a piece of the GLP-1 pie.
Personalized healthcare drives growth for Hims & Hers: AI is helping the company’s providers customize treatments for patients. If the strategy pays off, Hims & Hers may soon leave its competition in the dust.
Hackers took down a crucial piece of US healthcare payments infrastructure: UnitedHealth’s Change Healthcare still hasn’t recovered, leaving providers unpaid and people unable to get care. It’s an unwelcome reminder of how vulnerable the system is to disruption.
Where do consumers want to see prescription drug ads? They trust doctor’s offices the most. But we explain why pharma marketers won’t be deterred from advertising more on digital channels.